Jazz Pharmaceuticals to acquire rare disease company Gentium
Authored by James Sheppard Jazz Pharmaceuticals, based in Dublin, Ireland, recently announced that it had acquired Italian based rare disease drug company Gentium in a $1bn deal. The deal will give...
View ArticlePTC Therapeutics appoints Chief Medical Officer and communicates CHMP...
Authored by Karl Simpson For patients living with Duchenne Muscular Dystrophy, last year offered great hope but also disappointment. The momentum was building in the development of exciting new...
View ArticleDr John Martin – Gilead – Executive Leadership Series
Authored by James Sheppard At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr John Martin...
View ArticleDr Francois Nader – NPS Pharmaceuticals – Executive Leadership Series
Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Francois...
View ArticleBiosimilars – is global development a reality?
Dr Narayanan is the Managing Director of Biologicals Advice Limited. He offers independent advice on all aspects of medicine development with special expertise on biologicals, advanced therapies and...
View ArticleMinoryx gains Orphan Drug Designation in X-Linked Adrenoleukodystrophy
Authored by Karl Simpson Nestled in the Bio-Cat cluster in Barcelona, Spain is the orphan drug therapeutics company, Minoryx Therapeutics, which is developing new medicines for the treatment of inborn...
View ArticleWilson Therapeutics Raises $40m to advance development program
Authored by James Sheppard The Stockholm based rare disease biotech, Wilson Therapeutics, announced that it had raises $40m in series B funding. The funding was co-led by new investors Abingworth LLP...
View ArticleRare Disease Biotech Summit plc Appoints Erik Ostrowski as CFO
Authored by James Sheppard The Oxford Biotech cluster based rare disease biotech Summit plc has announced the appointment of a new Chief Financial Officer (CFO). Summit announced that Mr Erik Ostrowski...
View ArticleCelgene and BMS team up for cancer immunotherapy development
Authored by James Sheppard The two global biopharma giants, Celgene and BMS, have announced a collaboration to advance cancer immunotherapies across multiple tumour types. The partnership will see the...
View ArticleActavis bolsters infectious disease portfolio with Durata purchase
Authored by James Sheppard The global generics giant Actavis has announced a deal to acquire the Chicago based infectious disease specialist Durata Therapeutics. The deal is estimated to be worth in...
View Article
